Novotech Partners with Medidata to Accelerate Clinical Research into COVID-19
Leading Asia-Pacific CRO Novotech and Medidata partner to support three new research trials into COVID-19
SYDNEY – June 17, 2020 – Medidata, a Dassault Systèmes company, and the global leader in creating end-to-end solutions supporting the entire clinical trial process, today announced its ongoing collaboration with Novotech, a leading contract research organisation, in the fight against COVID-19.
Novotech has secured three new studies into COVID-19, leveraging Rave EDC and Rave RTSM Medidata technology, shortening the start-up time in proceeding with the new studies.
As countries around the world continue to battle COVID-19, the demand for a vaccine is a global need. Working together, Medidata and Novotech are committed to navigating the complex clinical trial landscape to ensure clinical trials are progressing efficiently, reducing the overall trial timeline and improving patient experience.
"In the fight against COVID-19, it is critical that we drive innovation and technology in the search for a vaccine. Data is a key component in research. It is essential that technology and data work to run efficient trials and smarter drug development," said Edwin Ng, Senior Vice President, General Manager Sales, APeJ, Medidata. "Medidata and Novotech have worked closely together in the context of COVID-19 to streamline processes from months to weeks. Working with leading technologies, we can focus on enhancing the quality of clinical data and the patient experience."
"Working on the frontline of research development for COVID-19, we are excited to continue our partnership with Medidata to support our quality clinical research across the region," said Andries Claassen, Director Biometrics at Novotech. "Novotech is well-positioned to drive research efforts across the Asia-Pacific region for COVID-19. Working with Medidata and the latest technology, we can deliver integrated clinical trial services in this extraordinary time."
Medidata is a wholly-owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,500 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in Asia-Pacific. Novotech has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotechnology companies.
Novotech was established in 1996, with offices in 11 locations across the region, and site partnerships with major health institutions.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. For more information, visit: https://novotech-cro.com
Senior Director, Head of Corporate Communications
Head of External Communications, Senior Writer